Home |  About BSI My BiosynthesisServices New ProductsDistributors | SpecialsGizmo |  Tech LoungeTestimonials Forum |  Contact Us Login
     
     
Bio-Synthesis Inc. Announces Exclusive Collaboration in the Area of Immune Agonists and Antagonists 
Bio-Synthesis Unveils Free Online Software ‘Peptide, Oligo, Protein Analysis’ Click on Gizmo 
All Highlights   All Events
 
  Enter Keyword  
   
 
Advance Search
 
     
   
   
   
   
   
 
 
Custom LNA Synthesis Nucleic Acid Synthesis LNA Oligos LNA Chimeras
 
Custom LNA* (Lock Nucleic Acid Synthesis)

Locked Nucleic Acid (LNA) was first described by Wengel and co-workers in 19981 as a novel class of conformationally restricted oligonucleotide analogues. LNA is a bicyclic nucleic acid where a ribonucleoside is linked between the 2'-oxygen and the 4'-carbon atoms via a methylene unit.

Oligonucleotides containing LNA exhibit unprecedented thermal stability towards complementary DNA and RNA2, which allows excellent mismatch discrimination. In fact the high binding affinity of LNA oligos is recommended for use in any hybridization assay that requires high specificity and/or reproducibility such as

Service Overviews
LNA Synthesis
LNA Modifications
Dual Labeled LNA
LNA Conjugations
LNA Oligo Chimeras
Resources
Dual labeled probes
In situ hybridization probe
SNP genotyping
DNA MicroArray expression analysis
Allele Specific PNA
mRNA sample preparation
Molecular Beacons and PCR primers
As a result of these significant characteristics, the use of LNA-modified oligos in antisense drug development is now coming under investigation4, and recently the therapeutic potential of LNA has been reviewed.5
BSI offers LNA synthesis great flexibility. For more information on custom LNA synthesis, call 800-227-0627 or write to us at biosyn@biosyn.com

Our services:

LNA Synthesis LNA Modification

Dual Labeled Probes

LNA Conjugations LNA Chimeras
 
Features:
Deprotected, desalted and ready to use
Multi-scale capacities
Purification by PAGE or RP-HPLC upon request
QC analysis by MALDI-TOF Mass spectrometry, HPLC, PAGE analysis
Fast delivery with high throughput capacity
   
References:
(1a) A.A. Koshkin, S.K. Singh, P. Nielsen, V.K. Rajwanshi, R. Kumar, M. Meldgaard, C.E. Olsen, and J. Wengel, Tetrahedron,1998, 54, 3607-3630.
(1b) S.K. Singh, P. Nielsen, A.A. Koshkin, and J. Wengel, Chem. Comm., 1998, (4), 455-456.
(2) L. Kværnø and J. Wengel, Chem. Comm., 1999, (7), 657-658.
(3) P. Mouritzen, A.T. Nielsen, H.M. Pfundheller, Y. Choleva, L. Kongsbak, and S. Møller, Expert Review of Molecular Diagnostics, 2003, 3(1), 27-38.
(4a) J. Kurreck, E. Wyszko, C. Gillen, and V.A. Erdmann, Nucleic Acids Res., 2002, 30, 1911-1918.
(4b)H. Ørum and J. Wengel, Curr. Opinion in Mol. Therap., 2001, 3, 239-243.
(5a) M. Petersen and J. Wengel, Trends in Biotechnology, 2003, 21(2), 74-81.
(5b) D.A. Braasch, D.R. Corey, Biochemistry, 2002, 41, 4503-4510.
     
*License Agreement: Locked-nucleic Acid (LNA) phosphoramidites are protected by EP Pat No. 1013661, US Pat No. 6,268,490 and foreign applications and patents owned by Exiqon A/S. Products are made and sold under a license from Exiqon A/S. Products are for research purposes only. Products may not be used for diagnostic, clinical, commercial or other use, including use in humans. There is no implied license for commercial use, including contract research, with respect to the products and a license must be obtained directly from Exiqon A/S for such use."
 

The most trusted name in Quality Custom Synthesis.